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Abstract
The dysregulation of gene expression is an enabling hallmark of cancer. Computational analysis of transcriptomics data
from human cancer specimens, complemented with exhaustive clinical annotation, provides an opportunity to
identify core regulators of the tumorigenic process. Here we exploit well-annotated clinical datasets of prostate cancer
for the discovery of transcriptional regulators relevant to prostate cancer. Following this rationale, we identify
Microphthalmia-associated transcription factor (MITF) as a prostate tumor suppressor among a subset of transcription
factors. Importantly, we further interrogate transcriptomics and clinical data to refine MITF perturbation-based
empirical assays and unveil Crystallin Alpha B (CRYAB) as an unprecedented direct target of the transcription factor
that is, at least in part, responsible for its tumor-suppressive activity in prostate cancer. This evidence was supported by
the enhanced prognostic potential of a signature based on the concomitant alteration of MITF and CRYAB in prostate
cancer patients. In sum, our study provides proof-of-concept evidence of the potential of the bioinformatics screen of
publicly available cancer patient databases as discovery platforms, and demonstrates that the MITF-CRYAB axis
controls prostate cancer biology.
Introduction
Balanced integration of intracellular circuits operates
within a normal cell to sustain physiological homeostasis.
Alterations in some, if not all, of these circuits converge in
changes on gene expression, which will eventually enable
the acquisition and sustenance of the hallmarks of cancer
cells1. This event emphasizes the importance of
maintaining the transcriptional homeostasis in normal
cells and places gene expression deregulation at the core
of cancer research interests.
In the last decades, transcriptomics data derived from
cancer specimens have become an important resource for
the classification, stratification, and molecular driver iden-
tification in tumors. We and others have demonstrated that
deregulation of gene expression is a key node for cancer
pathogenesis and progression2–6. Prostate cancer (PCa)
research exemplifies the effort in deciphering the genomics
and transcriptomics landscape of tumors, and extremely
valuable data have been generated7–13. In spite of the public
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availability of these relevant data, they are still under-
exploited by the scientific community to understand PCa
biology. In this regard, the computational tools and dataset
selection strategies to carry out these studies are a bottle-
neck for the cancer research field.
By combining integrated-bioinformatics screening of
clinically relevant PCa datasets with in vivo and in vitro
molecular biology assays, we have recently described the
metastasis suppressor activity of peroxisome proliferator-
activated receptor γ (PPARγ) coactivator alpha
(PGC1α)14,15. This transcriptional coactivator is a major
regulator of mitochondrial biogenesis and function, and
has an inherent capacity to integrate environmental sig-
nals and cellular energetic demands. This ability
empowers PGC1α to be a driver in shaping responses to
metabolic stress during different physiologic and
tumorigenic processes16. As might be expected due to its
fundamental role in normal and cancer scenarios, the
regulation of PGC1α expression, from the genomic to the
protein level, is complex and dynamic17. At the level of
mRNA expression, one of the well-defined direct reg-
ulators of PGC1α is the Microphthalmia-associated
transcription factor (MITF)18.
MITF is a basic helix-loop-helix leucine zipper
(bHLHZIP) transcription factor that regulates the
expression of lineage commitment programs that
are essential for propagation of the melanocyte lineage19.
The existence of different MITF transcript variants is the
result of both alternative splicing and promoter activa-
tion that results in the cell-type-specific expression of the
different MITF isoforms (A, CX, MC, C, E, H, D, B, M,
J)20. The melanoma-specific isoform M-MITF is the best
studied isoform and, despite some controversy, its
expression is generally deregulated in melanoma.
Although MITF alone cannot act as a classical oncogene,
it has been called a “lineage survival oncogene” for mel-
anoma19,21. Importantly, the presence or absence of the
M-MITF-PGC1α regulatory axis has stratification
potential in melanoma and informs on the efficacy of
BRAF inhibitor treatments18,22. Although the expression
of MITF has been detected in other types of tumors
different from melanoma23,24, its active role in the pro-
gression of these diseases, including PCa, remains
unexplored.
Crystallin Alpha-B (CRYAB) is a ubiquitous small heat-
shock protein that is expressed in response to a wide
range of physiological and nonphysiological conditions
preventing aggregations of denatured proteins. In a
wide variety of tumor types CRYAB has been found to
be overexpressed and associated with disease
progression25–29 and poor prognosis30,31. However, in
PCa and nasopharyngeal cancers, CRYAB expression is
decreased32,33, pointing at possible tumor-suppressive
activity of CRYAB in these cancer scenarios.
In the present study, by combining an exhaustive
interrogation of seven publically available PCa databases
with refined empirical assays, we have identified MITF as
a prostate tumor suppressor. In addition, we have
unveiled CRYAB as a novel direct target of the tran-
scription factor that is, at least in part, responsible for its
tumor-suppressive activity in PCa. Importantly, the
tumor-suppressive role for this novel MITF-CRYAB axis
is supported by the enhanced prognostic potential of a
signature based on the concomitant alteration of both
genes in PCa patients.
Results
Bioinformatics screening identifies MITF as a transcription
factor altered in prostate cancer
We have recently demonstrated that the reduced
expression of the transcriptional coactivator PGC1α is a
causal event for metastatic PCa14. We sought to identify
transcriptional regulators related to the alteration in
PGC1α expression. We designed a bioinformatics strategy
based on the analysis of 16 genes directly linked to the
regulation of PGC1A gene17,22,34–38, in order to identify
transcription factors that could be relevant to PCa biol-
ogy. For the candidate screen we applied selection criteria
based on the consistency of, first, the correlation with
PGC1A expression and second, the expression of each
individual candidate in seven publicly available PCa
datasets7,9–13 (Fig. 1a). We selected those candidates
whose expression in primary tumors correlated with
PGC1A (R ≥ 0.2 and p value ≤ 0.05 in more than 50% of
the datasets) (Supplementary Figure 1A) and was altered
when compared to normal specimens. For genes exhi-
biting various transcript variants, the correlation analysis
was initially performed using the average signal (Supple-
mentary Figure 1A) and, when available (only Taylor
dataset11), the correlation was confirmed in all the indi-
vidual isoforms (Supplementary Table 1). The transcrip-
tion factor MITF was the sole candidate that complied
with the established criteria. We observed a consistent
correlation between PGC1A and MITF in four out of the
seven datasets analyzed (Fig. 1b and Supplementary Fig-
ure 1A). In addition, not only the mean expression but
also the expression of the individual MITF isoforms were
reduced in primary tumor specimens when compared
with the normal prostate tissue samples (Fig. 1c and
Supplementary Figure 1B). Taken together, our data
reveal MITF as a PGC1A-associated transcription factor
that is consistently downregulated in PCa.
MITF exhibits tumor-suppressive activity in PCa
The expression profile of MITF in PCa, together with its
direct correlation with PGC1A, was suggestive of a tumor-
suppressive activity of the transcription factor. We first
examined the differential expression of the distinct
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mRNA isoforms of MITF in normal, PCa primary tumors,
and PCa cell lines (Supplementary Fig. 2A–C). MITFA
was the isoform predominantly expressed in the three
scenarios analyzed, and we pursued the studies further
with this isoform. Next, we aimed to analyze the biological
consequences of ectopic expression of MITFA in PC3
PCa cells. We transduced PC3 cells with a lentiviral vector
containing a doxycycline-inducible cassette for the
expression of MITFA resulting in the generation of the
PC3 TRIPZ-MITFA cell line. The induction of MITFA
expression (Fig. 2a, b) as well as the regulation of known
target genes, including PGC1A14,15 (Supplementary Fig. 2
D–E) was confirmed. We next evaluated the biological
outcome of MITFA ectopic expression in PC3 cells and
observed that its upregulation significantly reduced two-
dimensional and anchorage-independent growth (Fig. 2c,
Fig. 1 MITF expression correlates with PGC1A expression and is downregulated in PCa. a Schematic representation of candidate screening to
mediate PGC1A downregulation in PCa. Candidate selection was performed by applying two different selection criteria based on the consistency
within the datasets used (>50%): the expression of the candidate must be consistently (i) correlated with the PGC1A’s and (ii) altered in the disease.
b Correlation analysis between PGC1A and MITF expression in primary tumor (PT) specimens of different PCa datasets (refs. 9–11 and TCGA
provisional). Sample sizes: Grasso n= 45; Lapointe n= 13; Taylor n= 131 and TCGA provisional n= 495. c MITF expression in normal prostate and
primary tumor (PT) specimens in different datasets9–11. Correlation (b) and expression (c) data from Taylor dataset corresponds to the mean signal of
all isoforms of the transcripts. In (b) and (c), each dot corresponds to an individual specimen. Sample sizes: Grasso et al. (Normal, n= 12; PT, n= 45);
Lapointe et al. (Normal, n= 9; PT, n= 13); Taylor et al. (Normal, n= 29; PT, n= 131). Error bars represent s.e.m. Statistic test: Spearman correlation R
(b) and Mann−Whitney test (c). p, p- value
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d), with no effect of doxycycline treatment by itself14. In
line with its known function as an inhibitor of cell cycle
progression39, the increased expression of MITFA in PC3
cells resulted in a decrease in BrdU incorporation, a
surrogate readout of proliferation (Fig. 2e).
In order to ascertain whether the regulation of endo-
genous PGC1A (Supplementary Fig. 2E) was required for
the antiproliferative effect of MITFA in PC3 cells, we aim
at silencing PGC1A by using constitutive (pLKO)
expression of short hairpins against it (Supplementary
Fig. 2F). Transduction with the shRNA prevented the
upregulation of PGC1A upon MITFA induction (Sup-
plementary Fig. 2G) but the antiproliferative effect of the
transcription factor remained unaffected (Supplementary
Fig. 2H). These data suggested that the reduced pro-
liferation induced by MITFA was not dependent on the
regulation of endogenous PGC1A in PC3 cells.
Importantly, the overall reduction in cell proliferation
induced by MITFA was confirmed in vivo. Using sub-
cutaneous xenografts assays we observed that MITFA
overexpression in PC3 cells (Supplementary Fig. 2I) led to
a marked reduction in the tumor volume (Supplementary
Fig. 2J) and growth rate (Fig. 2f), with no changes in
angiogenesis (Supplementary Fig. 2K). Altogether these
results demonstrate that MITFA isoform exhibits tumor-
suppressive activity in PCa.
Candidate screening of genes mediating the tumor-
suppressive activity of MITF
In order to decipher the molecular mechanism driving the
tumor-suppressive role of MITFA, we performed gene
expression profiling of both doxycycline-treated and control
PC3 TRIPZ-MITFA cells and identified
101 probes that showed statistically differential signal
between both conditions (Supplementary Table 2; GEO
Series accession number GSE114345). We first performed a
gene enrichment analysis using the functional enrichment
tool contained in CANCERTOOL40 with those genes that
displayed upregulated expression (76 genes) upon MITFA
overexpression (Fig. 3a and Supplementary Table 3), as the
number of downregulated genes (25) was not sufficient to
obtain any gene enrichment. Next, we aimed at identifying
potential MITFA effectors of relevance in human PCa. To
this end, we established a threshold of 1.5-fold change over
MITFA noninduced cells, which resulted in eight probes
(corresponding to six annotated genes) upregulated upon
Fig. 2 MITF exhibits tumor-suppressive activity in PC3 PCa cell line. a, b Analysis and quantification of MITF expression by qRTPCR (a, n= 8)) and
western blot (b, representative experiment out of three independent ones) in PC3 TRIPZ-MITFA cells after treatment with 0.5 μgmL−1 doxycycline
(Dox). c Relative cell number quantification by crystal violet in doxycycline-treated and nontreated PC3 TRIPZ-MITFA cells. Data are normalized to day
0. Asterisks indicate statistics of five independent experiments. One representative experiment out of five is shown. Error bars represent standard
deviation. d, e Effect of MITF induction on anchorage-independent growth (d, soft agar; n= 4 independent experiments) and BrdU incorporation
(e, n= 3 independent experiments). f Impact of MITF induction in tumor growth rate of PC3 TRIPZ-MITFA cells (n= 7 animals per group; 14
injections/tumors). No dox: MITFA noninduced conditions; Dox: MITFA-induced conditions. Error bars represent s.e.m. (a, d, and e) or minimum and
maximum values (f). Statistic test: One-sample t test (a, d, and e) and Student’s t test (c, f *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 3 (See legend on next page.)
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the induction of the transcription factor (Supplementary
Table 2; yellow bold highlighted). We next performed
correlation analysis between MITF and each of the six dif-
ferentially expressed genes obtained from the microarray
(Fig. 3a and Supplementary Figure 3A). The correlation
analysis in PCa primary tumor specimens showed that a
single gene, Crystallin Alpha B (CRYAB), had a consistent
correlation (in more than 50% of datasets) with MITF, both
the mean of isoforms (Fig. 3b and Supplementary Fig-
ure 3A) and the individual isoform A (Supplementary
Table 4). The MITF−CRYAB correlation was confirmed
using an independent cohort of PCa patients from a local
hospital (Basurto cohort, Supplementary Figure 3A).
Moreover, the expression of CRYAB either at the level of
mRNA (from public datasets and Basurto cohort) and
protein (from Basurto cohort) was consistently down-
regulated through the progression of the disease (Fig. 3c, d
and Supplementary Figure 3B–D), supporting the associa-
tion of MITF and CRYAB expression in PCa.
The regulation of CRYAB expression by MITFA was
further validated in vitro by western blot and quantitative
real-time PCR (qRTPCR) in doxycycline-treated PC3
TRIPZ-MITFA cell lines and in vivo by qRTPCR in the
xenograft samples (Supplementary Figure 3E–G). MITF is
a transcription factor that regulates gene expression
through the DNA binding to E-boxes (Myc-binding
sites)19. In order to confirm the direct regulation of
CRYAB expression by MITFA, we screened the promoter
of the chaperon and performed chromatin immunopreci-
pitation assays in two Myc-binding sites (UCSC-Genome
browser; Supplementary Figure 3H). As predicted, upon
doxycycline treatment we detected differential binding of
MITFA in both regions of CRYAB promoter (Fig. 3e).
Taken together, these data presented CRYAB as a direct
target of MITFA and the best candidate to mediate its
tumor-suppressive activity in PCa.
CRYAB mediates the tumor-suppressive activity of MITF in
PCa
We next studied the functional relevance of CRYAB for
the tumor-suppressive activity of MITFA in PCa. Towards
this aim, we constitutively silenced the expression of
CRYAB by RNAi using two independent short hairpin
RNA (sh#1 and sh#2) in PC3 TRIPZ-MITFA cells. After
validating that RNAi was achieved (Fig. 4a and Supple-
mentary Figure 4A–C) the tumor-suppressive activity of
MITFA was monitored in control and CRYAB-silenced
conditions (PC3 TRIPZ-MITFA scr, sh#1 or sh#2 cell
lines). CRYAB silencing blunted the antiproliferative
effects of MITFA in vitro in two-dimensional and
anchorage-independent growth when compared with
scramble shRNA (Fig. 4b, c). Moreover, the reduction in
BrdU induced by MITFA was prevented when CRYAB
was silenced (Fig. 4d). Importantly, the requirement of
CRYAB for the tumor-suppressive activity of MITFA was
corroborated in vivo (Fig. 4e and Supplementary Fig-
ure 4D–F). The in vitro and in vivo data demonstrate that
the induction of CRYAB is a major effector involved in the
tumor-suppressive activity of the transcription factor
MITF in PCa.
We next asked whether the functional association
between MITF and CRYAB could be employed to identify
PCa patients with high disease aggressiveness. We thus
ascertained the stratification potential of the MITF-
CRYAB axis in PCa by means of consistency and
robustness. We download the mRNA expression raw data
together with the clinical data (recurrence or not recur-
rence) from Taylor11, Glinsky8, and TCGA7 datasets. The
individual or average expression signal of CRYAB and
MITF genes was calculated for each patient in each
dataset. Patients were separated by quartiles according
to the individual or average signal of CRYAB and
MITF genes and then Kaplan−Meyer survival curves
were plotted comparing patients with low expression
(Quartile 1—(Q1)) of the individual genes or the gene
combination (CRYAB and MITF) vs the rest of the cohort
(Q2+Q3+Q4). Strikingly, the signature formed by the
average signal of MITF and CRYAB outperformed
the prognostic potential of each individual gene,
strongly suggesting that the pathway described herein is
strongly associated to PCa aggressiveness (Fig. 4f and
Supplementary Figure 5).
(see figure on previous page)
Fig. 3 CRYAB is the candidate to mediate its tumor-suppressive activity in PCa. a Workflow of the candidate screening. b Correlation analysis
between MITF and CRYAB expression in primary tumor (PT) specimens of different PCa datasets. Sample sizes: Taylor, n= 131; Grasso, n= 49;
Lapointe, n= 13; TCGA provisional data, n= 495; and Glinsky, n= 78. c CRYAB expression in normal prostate and primary tumor (PT) specimens in
different PCa datasets9–13. Sample sizes: Taylor (N, n= 29; PT, n= 130); Grasso (N, n= 12; PT, n= 49); Varambally (N, n= 6; PT, n= 7); Lapointe et al.
(N, n= 9; PT, n= 13), and Tomlins (N, n= 22; PT, n= 32). Data from Taylor dataset correspond to the mean signal of all isoforms of the transcripts. In
(b) and (c), each dot corresponds to an individual specimen. d Western blot analysis of CRYAB expression in benign prostatic hyperplasia (BPH) and
PCa specimens from Basurto University Hospital cohort (BPH n= 7 patient specimens; PCa n= 14 patient specimens). e Chromatin
immunoprecipitation (ChIP) of exogenous MITF on CRYAB promoter in PC3 TRIPZ-MITFA cells after induction with 0.5 µgmL−1 doxycycline for 3 days
(n= 4–5). Binding to ANGPT4 was used as a negative control. Final data were normalized to IgG (negative-immunoprecipitation control) and to No
dox condition. No dox: MITFA noninduced conditions; Dox: MITFA-induced conditions. Statistic tests: Spearman correlation (b); Mann−Whitney test
(c); one-sample t test (e); Error bars represent s.e.m. *p < 0.05, **p < 0.01
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Fig. 4 CRYAB mediates the tumor-suppressor activity of MITF. a Analysis of MITFA and CRYAB protein expression in doxycycline-treated PC3
TRIPZ-MITFA cells transduced with shScramble (scr) or two independent shCRYAB (sh#1 and#2) (one representative experiment with technical
duplicates is shown; similar results were obtained in three independent experiments). b Relative cell number quantification by crystal violet in
doxycycline-treated and nontreated PC3 TRIPZ-MITFA cells, in the presence (scr) or absence (sh#1, 2) of CRYAB (n= 5 independent experiments).
Data are normalized to day 0 and represented as cell number at day 6 relative to No Dox condition (depicted by a dotted line). c, d Effect of CRYAB
silencing on anchorage-independent growth (c, soft agar; n= 4 independent experiments) and BrdU incorporation (d, n= 3 independent
experiments) in PC3 TRIPZ-MITFA cells after treatment with 0.5 μgmL−1 doxycycline. e Impact of CRYAB silencing on tumor growth rate of MITF-
induced cells (n= 10 animals per group-scr or sh#1; 2 injections per mice (scr No dox, n= 10 tumors; sh#1 No dox, n= 8 tumors; scr Dox, n= 6
tumors; sh#1 Dox, n= 11 tumors). f Association of the mean signal of MITF and CRYAB with disease-free survival (DFS) in three PCa datasets (Q1: first
quartile distribution; rest: second, third, and fourth quartile distribution. Sample sizes: Taylor, primary tumors n= 131; TCGA provisional data primary
tumors n= 490; Glinsky, primary tumors n= 78. No dox: MITFA noninduced conditions; Dox: MITFA-induced conditions. HR: hazard ratio. Statistic
tests: One-sample t test (b, c and d—No dox vs Dox conditions); Unpaired Student’s t test (t) (b, c and d—Dox-treated scr vs Dox-treated sh#1/2);
Log-rank (Mantel–Cox) test (f). Error bars represent s.e.m. */$p < 0.05, **/$$p < 0.01. Asterisks indicate statistic between No dox and Dox conditions
and dollar symbol between Dox-treated scr and Dox-treated sh#1 or 2
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Our data provide solid evidence of an unprecedented
MITF-CRYAB transcriptional axis that exerts tumor-
suppressive activity in PCa and could positively contribute
to disease prognosis.
Discussion
Technological advances in the molecular understanding
of cancer have led to a paradigmatic change in the way
that we combat the disease41. We are now able to
deconstruct a tumor at a molecular level using genomics,
transcriptomics, proteomics, and metabolomics42. This, in
turn, enables us to foresee, identify, and demonstrate the
potential of patient stratification3,14,43. Specifically, the
transcriptomics characterization of tumors is an invalu-
able strategy to identify clinically relevant genes that play
key roles in the progression of cancer, especially for those
types with poorer prognosis14. Thus, the comprehensive
and integrative analysis of gene expression changes and
clinical parameters in cancer has become a mainstream in
cancer research44–46. Mining cancer-associated tran-
scriptome datasets is an emerging approach used by top
cancer research groups, but better tools are needed to
increase its power and user-friendliness. In order to face
this challenge, new interfaces to exploit OMICs data, such
as cBioportal and CANCERTOOL45,47,40, are being
designed to help scientists interrogate, integrate, and
visualize large amount of information contained on
multiple credible and qualified cancer datasets.
In the present study, we exploited publicly available and
well-annotated (transcriptomics and clinical data) PCa
databases together with experimental assays to describe a
novel tumor-suppressive activity of the transcription fac-
tor MITF in PCa, which is executed, at least in part,
through the direct regulation of CRYAB expression. The
identification of MITF emanates from the screening of
reported upstream regulators of PGC1A. It is worth
noting that transcriptome-wide correlative study with the
gene of interest could represent a complementary
approach to predict candidate upstream regulators and
downstream effectors.
The functional implication of MITF in cancer has been
best defined in melanoma, in which the expression of the
transcription factor is heterogeneous. Although some
controversy exists regarding its oncogenic role in mela-
noma, MITF has been defined as a “lineage survival
oncogene” with no data pointing out at a tumor-
suppressive function19,21,39,48–51. Even though the
expression of MITF has been detected in other cancer
types23,24,52, no data supporting a functional role of MITF
deregulation have been reported yet in a cancer scenario
different from melanoma.
Here we show that MITF is downregulated in PCa when
compared with normal specimens, in contrast to the
elevated expression reported in hepatocellular carcinoma
and chronic myeloid leukemia23,52. Moreover, the novelty
of our study relies on the observation and definition of the
tumor-suppressive activity of MITF in PCa. In this con-
text, MITF upregulation was associated with a reduction
in cell proliferation and DNA replication. As occurs in
melanoma, the modulation of MITF expression in PCa
cells induces the expression of the cell cycle inhibitor p21
but no changes in the cell cycle inhibitor p16 were
observed (data not shown). Thus, our results in PCa are in
line with the canonical function of MITF in cell cycle
progression and proliferation in melanoma39,50,51.
It is important to highlight that the tissue-specific dif-
ferences in MITF expression among different cancer types
suggest that in order to fully comprehend MITF’s role in
cancer, its expression and function has to be analyzed in
the context of each particular cell and tissue type.
CRYAB is a member of the small heat-shock protein
family that functions as stress-induced molecular cha-
perone. It inhibits the aggregation of denatured proteins,
promotes cell survival, and inhibits apoptosis in the
context of cancer53–55. Paradoxically, CRYAB is highly
expressed in some cancer types but decreased in others
and in both scenarios an association with cancer pro-
gression and prognosis has been reported25,26,28–32,56–60.
In spite of the amount of information regarding the
changes in CRYAB expression in cancer, the transcrip-
tional regulation of this chaperone has been poorly
explored56. In this study, we described a novel direct
transcriptional regulation of CRYAB by MITF. Although
there is no direct nor mechanistic evidence of the MITF-
CRYAB transcriptional axis in other cancer types, in
melanoma both MITF and CRYAB expression are upre-
gulated by BRAF/MEK-inhibitor treatments57,60, sug-
gesting that this regulation can go beyond both PCa
scenario. Indeed, we observed that the correlation
between MITF and CRYAB is also present in colorectal
cancer, but not in breast nor lung cancer (data available in
CANCERTOOL40).
In our study, the MITF-CRYAB transcriptional axis is
reduced and exerts tumor-suppressive activity in PCa.
This is in agreement with the reduced expression of
CRYAB observed in PCa patients and its previous con-
sideration as a protective gene against PCa32. Yet, the
exact molecular mechanism underlying the tumor-
suppressive activity of CRYAB remains to be elucidated.
Importantly, in the present manuscript, the extensive
interrogation of PCa transcriptomes and associated clin-
ical data has led us to propose the transcriptional axis
MITF-CRYAB as a potential prognostic biomarker in
PCa. The individual expression of CRYAB and MITF has
been previously associated with poor prognosis in various
tumor types26,29–31,58,59 and to therapy response in mel-
anoma61–63. However, our data showing enhanced prog-
nostic potential of the combined signature provides a new
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and exciting perspective of the functional interaction of
these genes in PCa.
Our study endorses the potential of transcriptional
deregulation analysis, as either a cause or a consequence
of cancer, and its impact to support the discovery of novel
cancer-related genes and long-term development of novel
cancer treatment strategies.
Materials and methods
Cell culture and reagents
Human prostate carcinoma cell lines (PC3) were pur-
chased from Leibniz-Institut DSMZ—Deutsche Samm-
lung von Mikroorganismen und Zellkulturen GmbH, who
provided authentication certificate. The cell line used in
this study was not found in the database of commonly
misidentified cell lines maintained by ICLAC and NCBI
Biosample. Cells were transduced with a modified TRIPZ
(Dharmacon) doxycycline-inducible lentiviral construct in
which the RFP and miR30 region was substituted by HA-
Flag-MITF. Lentiviral shRNA constructs targeting
PGC1A (#1-TRCN0000001165 and #2-TRCN000000
1166) and CRYAB (#1-TRCN0000010822 and #2-
TRCN0000010823) were purchased from Sigma and a
scramble shRNA (hairpin sequence: CCGGCAACAAGA
TGAAGAGCACCAACTCGAGTTGGTGCTCTTCATC
TTGTTG) was used as control. For PGC1A and CRYAB
shRNAs, Puromycin resistance cassette was replaced by
Hygromycin cassette from pLKO.1 Hygro (Addgene Ref.
24150) using BamHI and KpnI sites. Cell lines were
routinely monitored for mycoplasma contamination and
quarantined while treated if positive. Doxycycline hyclate
(Dox) and Puromycin were purchased from Sigma, and
Hygromycin from Invitrogen.
Xenotransplant assays
All mouse experiments were carried out following the
ethical guidelines established by the Biosafety and Welfare
Committee at CIC bioGUNE. The procedures employed
were carried out following the recommendations from
AAALAC. Xenograft experiments were performed as
previously described14, injecting 106 cells per condition in
two flanks per mouse (Nu/Nu immunodeficient males;
6–12 weeks of age). PC3 TRIPZ-HA-MITFA cells
alone or under CRYAB silencing were injected in each
flank of nude mice and 24 h post-injections mice were
fed with chow or doxycycline diet (Research diets,
D12100402).
Patient samples
All samples were obtained from the Basque Biobank for
research (BIOEF, Basurto University Hospital) upon
informed consent and with evaluation and approval from
the corresponding ethics committee (CEIC code
OHEUN11-12 and OHEUN14-14).
Molecular assays
Western blot was performed as previously described14.
Antibodies used: HA-Tag (Cell Signalling #3724; dilution
1:10,000); MITF (Thermo Fisher Scientific MA5-14146;
dilution 1:1000); β-Actin (Cell Signalling #3700; dilution
1:2000); GAPDH (clone 14C10; Cell Signalling #2218;
dilution 1:1000); CRYAB (Cell Signalling #45844s; dilu-
tion 1:1000).
RNA was extracted using NucleoSpin® RNA isolation
kit from Macherey-Nagel (ref: 740955.240C). For patients
and animal tissues a Trizol-based implementation of the
NucleoSpin® RNA isolation kit protocol was used as
reported14. One microgram of total RNA was used for
cDNA synthesis using MaximaTM H Minus cDNA
Synthesis Master Mix (Invitrogen M1682). Quantitative
Real-Time PCR (qRTPCR) was performed as previously
described14. Universal Probe Library (Roche) primers and
probes employed are detailed in Supplementary Table 5.
GAPDH (Hs02758991_g1) housekeeping assay from
Applied Biosystems was used for data normalization.
For transcriptomics analysis in PC3 TRIPZ-HA-Flag-
MITFA cells, Illumina whole genome -HumanHT-
12_V4.0 (DirHyb, nt) method was used as reported14. A
hypergeometric test was used to detect enriched dataset
categories.
Cellular assays
Cell number quantification with crystal violet was per-
formed as referenced14.
For starvation experiments 100,000 cells per well were
seeded in a six-well plate. Cells were initially plated in 10%
FBS media for 24 h and then the media was changed to
FBS free media and left overnight.
Soft agar assays were performed as previously descri-
bed14, seeding 5000 cells per well in six-well plates.
For BrDu incorporation, cells were seeded on glass
cover slips in 12-well plates and after 4 days, cells were
incubated with 3 µg mL−1 BrDu (Sigma B5002). Cells
were fixed with 4% para-formaldehyde, permeabilized
with 1% Triton X-100 and incubated with a monoclonal
anti-BrDu (MoBU-1) antibody (Invitrogen B35128) at a
1:100 dilution. Images were obtained with an AxioImager
D1 microscope (Zeiss). At least three different areas per
cover slip were quantified.
Chromatin immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was performed
using the SimpleChIP® Enzymatic Chromatin IP Kit (Cat:
9003, Cell Signalling Technology, Inc). Four million PC3
cells were grown in 150mm dishes either with or without
0.5 µgmL−1 doxycycline during 3 days. Cells from three
150mm dishes were cross-linked with 35% formaldehyde
for 10min at room temperature. Glycine was added to
dishes during 5min at room temperature. Cells were then
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washed twice with ice-cold PBS, and scraped into PBS+
PMSF. Pelleted cells were lysed and nuclei were harvested
following the manufacturer’s instructions. Nuclear lysates
were digested with micrococcal nuclease for 20min at 37 °C
and then sonicated in 500 μL aliquots on ice for 6 pulses of
20 s using a Branson sonicator. Cells were held on ice for
at least 1min between sonications. Lysates were clarified at
11,000 × g for 10min at 4 °C, and chromatin was stored at
−80 °C. HA-Tag polyclonal antibody (Cat: C29F4, Cell
Signalling Technology) and IgG antibody (Cat: 2729, Cell
Signalling Technology, Inc), were incubated overnight
(4 °C) with rotation and protein G magnetic beads were
incubated 2 h (4 °C). Washes and elution of chromatin were
performed following the manufacturer’s instructions. DNA
quantification was carried out using a Viia7 Real-Time PCR
System (Applied Biosystems) with SybrGreen reagents and
primers that amplify the predicted MITFA binding region
to CRYAB (region 1; For: ttgtttcctcgtagggcttg, Rev: tttca-
gagccaggagagagc- region 2; For: tctggaatggtgatgtcagg, Rev:
attgggtgtggacagaaagc) and ANGPTL4 (For: gttgacccggctca-
caat, Rev: ggaacagctcctggcaatc) as a negative binding
control.
Whole-genome gene expression characterization
Whole-genome expression characterization was con-
ducted using Human HT12 v4 BeadChips (Illumina Inc.).
In brief, cRNA synthesis was obtained with TargetAmp™
Nano-g™ Biotin-aRNA Labeling Kit for the Illumina®
System, Epicentre (Cat. Num. TAN07924) and sub-
sequent amplification, labeling and hybridization were
performed according to Whole-Genome Gene Expression
Direct Hybridization Illumina Inc.’s protocol. Raw data
were extracted with GenomeStudio analysis software
(Illumina Inc.) in the form of GenomeStudio’s Final
Report (sample probe profile).
Bioinformatics analysis and statistics
Database normalization
All the datasets used for the data mining analysis were
downloaded from GEO and TCGA. Referenced acces-
sions: TCGA https://cancergenome.nih.gov/, Grasso et al.,
GEO: GSE35988 (9); Lapointe et al., GEO: GSE3933 (10);
Taylor et al., GEO: GSE21032 (11); Tomlins et al., GEO:
GSE6099 (12); Varambally et al., GEO: GSE3325 (13); and
Glinsky et al (8). GEO-downloaded data were subjected to
background correction, log2 transformation and quartile
normalization. In the case of using a preprocessed dataset,
this normalization was reviewed and corrected if required.
TCGA data were downloaded as upper quartile normal-
ized RSEM count, which was been log2 transformed.
Quartile analysis in disease-free survival
Patients biopsies from primary tumors were organized
into four quartiles according to the expression of the gene
of interest in three datasets. The recurrence of the disease
was selected as the event of interest. Kaplan−Meier esti-
mator was used to perform the test as it takes into
account right-censoring, which occurs if a patient with-
draws from a study.
Correlation analysis
Spearman correlation test was applied to analyze the
relationship between paired genes.
Gene enrichment
The recently published tool, CANCERTOOL40, harbors
11 independent enrichment databases, including the basic
Gene Ontology analysis (GO, biological process (GOBP),
molecular function (GOMF) and cell compartment
(GOCC)), pathways and pathophysiological processes
(KEGG, Biocarta, Reactome, Biocarta, Onco, DOSE,
HIPC, Connectivity Map), and the upstream regulatory
cue prediction tool (TFT, MIR). The prevalence of such
functions within the gene list was analyzed, and statistical
significance of the associations sieved according to the
Benjamini–Hochberg correction (adjusted p value).
Statistical analysis
No statistical method was used to predetermine the
sample size. The experiments were not randomized. The
investigators were not blinded to allocation during
experiments and outcome assessment. Unless otherwise
stated, data analyzed by parametric tests are represented
by the mean ± s.e.m. of pooled experiments and median ±
interquartile range for experiments analyzed by non-
parametric tests. n values represent the number of inde-
pendent experiments performed, the number of individual
mice or patient specimens. For each independent in vitro
experiment, at least two technical replicates were used
and a minimum number of three experiments were done
to ensure adequate statistical power. For data mining
analysis Student’s t test for two component comparisons.
In the in vitro experiments, normal distribution was
confirmed or assumed (for n < 5) and Student’s t test was
applied for two component comparisons. In the statistical
analyses involving fold changes, one-sample t test with a
hypothetical value of 1 was performed. The confidence
level used for all the statistical analyses was of 95% (alpha
value= 0.05). Two-tail statistical analysis was applied for
experimental design without predicted result, and one-tail
for validation or hypothesis-driven experiments.
Gene expression array data analysis
First, raw expression data were background-corrected,
log2-transformed, and quantile-normalized using the lumi
R package64, available through the Bioconductor reposi-
tory65,66. Probes with a “detection p value” lower than 0.01
in at least one sample were considered expressed. For the
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detection of differentially expressed genes, a linear model
was fitted to the probe data and empirical Bayes moder-
ated t statistics were calculated using the limma67 package
from Bioconductor. Adjusted p values were estimated
with Benjamini−Hochberg false discovery rate method
(https://www.jstor.org/stable/2346101)68. Only genes with
differential fold-change (FC) > 1.5 or <−1.5 and an
adjusted p value < 0.05 were considered as differentially
expressed. The transcriptomics data generated in this
publication have been deposited in NCBI’s Gene Expres-
sion Omnibus and are accessible through GEO Series
accession number GSE114345.
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